Author: toxlaw

Methamphetamine increased willingness to choose a more demanding laboratory task, but those changes were not correlated with drug-induced euphoria or liking in a controlled study of healthy adults. Feeling better and choosing greater effort were separate measured outcomes.

A single dose and a specific decision task

Hahn and colleagues compared 20 mg oral methamphetamine with placebo in a double-blind, within-subject design. Participants attended an orientation session and two four-hour drug sessions separated by at least three days. Behavioral tasks began one hour after the capsule.

The Effort Expenditure for Rewards Task offered a choice between an easier option and a harder option. The easy task required 30 key presses with the right index finger in seven seconds for a possible $1 reward. The hard task required 100 presses with the left little finger in 21 seconds for possible rewards from $1.24 to $4.21. Reward probabilities were 12%, 50% or 88%, disclosed before the choice.

The endpoint was how frequently participants selected the harder task. It was not an examination score, work productivity measurement or test of driving skill. Choosing more effort is not automatically the best decision in every setting.

Why the denominators differ

Of 113 participants who completed the study, 96 remained in the behavioral analysis after exclusions for missing data, invariant hard/easy choices or sessions containing only timeouts. The final behavioral sample included 48 men and 48 women.

Five additional participants were excluded from computational modeling because their choices were better described by a bias model, leaving 91. Subjective analyses had 94 participants for euphoria and 92 for drug liking. These are analysis-specific samples; they are not four independent experiments or a single sample of 113 with complete observations.

Baseline effort changed the size of the response

Investigators divided participants into two groups of 48 using orientation-session task performance. Methamphetamine increased overall hard-task selection in both baseline groups, with a larger increase in the low-effort group. Reported within-group standardized effects were d = 0.76 for the low-baseline group and d = 0.42 for the high-baseline group.

The higher-baseline group therefore should not be described as showing no behavioral response. The more selective null finding concerned a computational parameter, not the overall frequency of hard choices.

What the computational model added

The model estimated sensitivity to effort cost, reward probability and consistency of choice. Methamphetamine reduced the estimated effort-cost parameter in the low-baseline group, but the corresponding comparison in the high-baseline group was nonsignificant. The drug did not significantly alter the probability-sensitivity parameter.

These are model-derived quantities fitted to choices. They are not direct measurements of dopamine, physical stamina or a person’s real-world motivation. The authors did not measure dopamine function, and proposed neurotransmitter explanations remain hypotheses.

Effort changes did not track euphoria

Outcome pair	Reported correlation	Interpretation
Drug-associated hard-choice change and euphoria change	r = 0.007; p = 0.948	No significant relationship detected
Drug-associated hard-choice change and drug-liking change	r = −0.031; p = 0.768	No significant relationship detected

The drug increased euphoria and liking at the group level, yet people with larger subjective changes did not reliably show larger effort changes. A group effect on two measures does not imply that the two changes correlate across individuals.

Conversely, nonsignificant correlations do not prove that mood and motivation can never interact. They define the relationship observed with these measures, participants and experimental conditions.

Limits on claims about enhancement or impairment

The sample consisted of selected healthy adults aged 18–35, free of major psychiatric conditions. One dose was tested. A median split creates study-specific categories, rather than identifying a clinical disorder or a stable diagnosis of low motivation.

The experiment provides no blood-concentration cutoff, validated impairment classification or basis for deciding whether an individual drove safely. It also does not establish efficacy for depression or ADHD. The narrow finding is a change in laboratory effort-based choices that was larger in lower baseline performers and did not correspond to the measured subjective drug effects.

Primary scientific source

Hahn EC, Molla H, Cooper JA, DeBrosse J, de Wit H. Effects of methamphetamine on human effort task performance are unrelated to its subjective effects. Psychopharmacology. 2026;243:199–209; first published online July 8, 2025. doi:10.1007/s00213-025-06853-4. Original commentary on the supplied controlled human study; publication year follows the issue citation.

Feeling euphoric after methamphetamine and showing a stronger brain response to a monetary reward cue were not interchangeable outcomes in a 2025 controlled human study. The drug increased positive subjective effects, but its effects on reward-related imaging signals did not track those feelings in the expected way.

What did participants receive?

Molla and colleagues used a randomized, double-blind, within-subject comparison of a single 20-mg oral methamphetamine dose with placebo. Healthy adults attended separate imaging sessions at least 72 hours apart. Capsules were administered at 9:30 a.m.; participants were taken to a 75-minute MRI session after further assessments at 10:30 a.m.

The study enrolled 101 participants. Thirteen were excluded from imaging analysis because of excessive movement, poor task engagement or technical problems, leaving 88 participants: 47 men and 41 women. Subjective-effect analyses used their own available observations, including some analyses with 101 participants. “Eighty-eight” is the imaging denominator, not a universal denominator for every result.

The task separated anticipation from outcome

During the Monetary Incentive Delay task, cues signaled possible gains, possible losses or neutral outcomes. Participants responded to a target, with successful responses earning a gain or avoiding a loss. The task adjusted target duration to regulate success rates.

The investigators separately examined brain responses while participants anticipated an outcome and when feedback disclosed what occurred. Reward anticipation, loss anticipation and receipt of an outcome are distinct processes. A signal in one phase cannot simply be described as “more reward activity” across the entire task.

Positive feelings increased; the hypothesized imaging pattern did not

Methamphetamine increased drug liking, euphoria and stimulant-like subjective effects compared with placebo. It also increased heart rate. These observations confirm effects under the study conditions; they do not determine what an individual experienced outside the experiment.

In the predefined imaging regions, the clearer drug effect concerned anticipation of monetary loss. Ventral striatal activation increased for loss versus neutral cues, with p = 0.009. The caudate finding during gain anticipation was a nonsignificant trend, p = 0.087. It should not be presented as a demonstrated reward-anticipation increase.

The drug did not significantly change the predefined regional responses during outcome feedback. An exploratory whole-brain analysis found a different signal in the right precuneus during loss feedback. That exploratory result should remain separate from the predefined region-of-interest findings.

A baseline association was not the same as a drug-induced association

Comparison	Reported result	What it does not establish
Caudate reward-cue activity under placebo versus later drug-associated euphoria	Positive association, Spearman r = 0.32, p = 0.002	A validated individual diagnostic test
Drug-induced caudate activity change versus euphoria change	No significant association, r = −0.17, p = 0.1	Proof that all reward mechanisms are independent
Thalamic loss-anticipation signal versus stimulant-like ratings	Initial association did not survive multiple-comparison correction	A confirmed relationship after correction

The placebo-session association concerns differences between people in a baseline condition. The drug-minus-placebo comparison concerns changes produced across conditions. Switching between these comparisons can turn the paper’s actual result into a stronger—and unsupported—mechanistic claim.

Why the null findings matter

The results do not show that methamphetamine has no effect on reward processing. They show that particular imaging and subjective endpoints did not move together as hypothesized at this dose and task. The authors discuss possible explanations involving tonic signaling and cue responses, but the experiment did not directly measure synaptic dopamine.

A 43-person subset had appeared in an earlier report. That earlier imaging sample and this expanded analysis should not be counted as wholly independent replications.

Can these scans identify impairment?

This study did not validate a blood-concentration threshold, a driving-impairment test or a method for reconstructing a person’s state during an earlier event. BOLD imaging, subjective reports and cardiovascular measurements are different endpoints. There was no basis to convert a regional imaging change into an individualized degree of intoxication.

The participants were selected healthy young adults, most with little or no prior stimulant exposure. Generalization to chronic use, other doses, other routes, clinical populations or nonmonetary rewards requires additional evidence.

Primary scientific source

Molla H, DeBrosse J, Keedy S, Lee R, de Wit H. Effects of methamphetamine on two measures of reward: Euphoria and neural activation to reward cues. Neuropsychopharmacology. 2025;50:1298–1304. doi:10.1038/s41386-025-02110-6. Original commentary on the supplied controlled human study.

A 2024 study found that d-amphetamine improved selected memory outcomes in aged male rats and restored a laboratory measure of norepinephrine release in brain tissue. The findings are experimental evidence in a particular animal model. They do not establish that amphetamine prevents dementia, reverses human brain aging, or improves every cognitive function.

What was tested—and in which animals?

Scognamiglio and colleagues studied young and aged male Fischer 344 rats using several experiments: neurotransmitter release from brain slices, novel-object recognition, a spatial-learning maze, and microscopic assessment of dendritic spines. These were different measurements in different experimental groups. Their observations should not be combined into a fictitious single large clinical trial.

The methods describe young rats aged 2–4 months and aged rats 18–22 months; portions of the results and figure legends describe aged animals as 18–24 months. Those source descriptions should be retained rather than converted into an exact human age equivalent.

The brain-slice experiment measured release, not a blood drug level

The investigators loaded cerebral cortical and hippocampal tissue with radiolabelled norepinephrine, then measured fractional release under specified stimulation conditions. Glutamate-stimulated release was lower in tissue from aged animals. Release produced by a depolarizing potassium stimulus was not comparably reduced.

Adding 1 micromolar d-amphetamine to the tissue preparation restored the reduced glutamate-stimulated release toward the level measured in untreated young tissue. This concentration refers to the experimental preparation. It is not a rat plasma concentration, a human therapeutic target, or a forensic blood threshold.

The contrast between glutamate and potassium stimulation matters. The experiment supports a more specific vulnerability in the tested signaling process than a claim that all neurotransmitter release had failed with aging.

Acute treatment improved one memory outcome in aged rats

For novel-object recognition, the acute experiment included 26 young and 29 aged rats. A single intraperitoneal dose of 0.5 mg/kg d-amphetamine was administered 20 minutes before the test phase, following a 24-hour interval after training. The outcome was preferential exploration of a novel versus familiar object.

Aged rats improved relative to their saline performance; young rats did not show a statistically significant acute improvement. That null finding is part of the result. The experiment does not support an unqualified claim that amphetamine enhanced recognition memory in every group.

In a further pharmacological test, low-dose propranolol pretreatment blocked the amphetamine-associated improvement. This supports involvement of beta-adrenergic signaling under the experimental conditions. It does not establish that norepinephrine is the only possible contributor to every amphetamine effect.

Chronic administration and persistence were separate questions

The chronic regimen used drinking water to target 0.25 mg/kg/day during the first week and 0.5 mg/kg/day during the second. Water consumption and body weight informed the estimated regimen; this differs from an individually injected dose.

Improved novel-object recognition remained evident two weeks after treatment stopped but was not maintained as a preference for the novel object at ten weeks. The young-group overall treatment analysis was nonsignificant, although some post-hoc comparisons were significant. Those distinctions argue against describing the benefit as uniform or permanent.

Experiment	Unit and outcome	Interpretive boundary
Novel-object recognition	Individual rats; exploration preference	Not human everyday memory
Barnes maze	Four groups of 8, 10, 7 and 9 rats; latency and errors	Different cohort from recognition testing
Spine microscopy	5–6 rats per group, with sampled dendritic segments	Segments are not independent animals

What follows for human or forensic interpretation?

The maze and microscopy findings add converging preclinical observations, but neither measures human impairment, safe driving, or dementia prevention. The study used male animals from one strain, selected tasks, specific regimens and brain-tissue assays. A change in dendritic spine morphology is not a clinical diagnosis or proof of functional recovery in a person.

The defensible conclusion is that d-amphetamine altered particular biological and behavioral endpoints in this aged-rat model. Human efficacy, individualized dosing and clinical safety require separate evidence.

Primary scientific source

Scognamiglio S, Aljohani YM, Olson TT, Forcelli PA, Dezfuli G, Kellar KJ. Restoration of norepinephrine release, cognitive performance, and dendritic spines by amphetamine in aged rat brain. Aging Cell. 2024;23:e14087. doi:10.1111/acel.14087. Original commentary on the supplied animal and ex-vivo research; no source figures reproduced.

An increase in blood specimens submitted for drug analysis does not, by itself, establish an equal increase in amphetamine use among drivers. Testing volume reflects enforcement, selection and analytical practices as well as underlying exposure. Historical Swedish forensic research illustrates why those pathways must be separated.

What changed in the historical account?

In a 2007 paper, Alan Wayne Jones described a greater than tenfold increase in drug-impaired-driving specimens submitted for toxicological analysis following Sweden’s introduction of zero-concentration legislation in 1999. The discussion also described changes in police training and motivation to pursue cases.

This is the paper’s historical account of an earlier Swedish system. It is not a statement of current law in Sweden or elsewhere. The scientific issue is how a change in the process generating a dataset affects interpretation of its counts.

A specimen count is the end of a selection process

Before a specimen enters a forensic database, a driver must encounter enforcement, be selected for further investigation, undergo collection and have the material submitted. Laboratory scope, reporting limits and confirmation criteria then affect what is recorded as positive.

If any stage changes, the final count can change even without an equivalent change in exposure among all drivers. Better recognition of suspected drug use might increase sampling. A change in the evidence required for a charge might increase submissions. Neither possibility rules out a real prevalence change, but both prevent the count alone from establishing it.

Keep three denominators separate

Quantity	Denominator needed	Question answered
Submission volume	Defined period and submitting system	How much testing work entered the system?
Positivity among submissions	Specimens tested under stated methods	How often was a target found in the selected material?
Prevalence among drivers	A sufficiently representative driver population	How common was exposure in the population of interest?

These are different quantities. A high positivity fraction among people selected because of suspected use need not resemble prevalence among drivers generally. Submission volume also need not equal a count of unique people unless repeat encounters have been identified.

What the 300-driver sample can contribute

Jones’s main analysis selected 300 suspected drivers with amphetamine as the only identified psychoactive drug in blood. Its concentration distribution describes that selected group. It does not provide the total driver population, driving distance, enforcement contacts or an unexposed comparison group required to estimate a population exposure rate or crash risk.

The smaller retrospective clinical sample of 70 answered another question about concentration and examination classifications. It cannot be repurposed into a before-and-after population survey. Changing the question requires an appropriate denominator and design, not merely a larger-looking number.

How should a trend claim be evaluated?

Ask whether the enforcement area, study period, stop criteria, specimen types, analytical panel and reporting thresholds remained comparable. Identify unique individuals when the intended conclusion concerns people rather than specimens or encounters. Look for an independent population denominator and explain any missing coverage.

For a causal claim about legislation or training, a temporal sequence alone is insufficient. The paper’s narrative identifies plausible influences on submissions; it does not isolate their individual effects in a controlled policy experiment.

What can be said accurately?

A laboratory may accurately report that it received more specimens or identified more positive specimens under stated procedures. The additional claim that drug use increased by the same factor requires further evidence. Likewise, a selected forensic database cannot establish that a specific exposure caused a crash.

The practical lesson is to describe the outcome actually counted. Testing activity, selected-sample positivity, population exposure and event causation should each retain their own evidentiary foundation.

Scientific source

Jones AW. Age- and gender-related differences in blood amphetamine concentrations in apprehended drivers: lack of association with clinical evidence of impairment. Addiction. 2007;102:1085–1091. Introduction, selection methods and discussion. doi:10.1111/j.1360-0443.2007.01802.x. Historical observational research and methodological commentary.

The strongest reported subjective methamphetamine effect need not occur at the time of the highest measured plasma concentration. Logan’s 2002 review describes a smoking study in which the subjective peak preceded the plasma peak by roughly two to three hours. A concentration curve and a person’s experience therefore cannot be treated as the same clock.

What does “peak” mean?

A pharmacokinetic peak concerns a measured concentration in a named specimen. A subjective peak concerns a rating or reported experience. A performance peak or deficit concerns an objective task. Each requires its own endpoint, measurement schedule and comparison condition.

These distinctions are especially important when someone uses the phrase “peak intoxication.” Without identifying which outcome was measured, the phrase may silently combine exposure, feeling and functional ability into one conclusion.

What the supplied historical source reports

In its discussion of acute dosing, Logan’s narrative review summarizes smoking and intravenous methamphetamine research. It reports peak subjective effects approximately 18 minutes after smoking began and 17 minutes after intravenous injection. For smoking, it states that the subjective peak preceded peak plasma concentration by approximately two to three hours, which the review treats as evidence of acute tolerance.

In the pharmacokinetic discussion, the review describes smoking experiments with a nominal 30-mg methamphetamine hydrochloride dose, an average estimated intake of 22 mg, and a mean peak plasma concentration of 0.047 mg/L at around 2.5 hours, followed by a plateau lasting about another two hours. The nominal material available and the estimated amount taken in were different quantities. Those values should not be collapsed into an exact administered systemic dose.

These findings are reported through the supplied 2002 review. The underlying experiments were not independently reanalyzed for this article. The numbers describe historical controlled conditions; they do not provide a reconstruction rule for an unknown exposure.

Acute tolerance is not the same as clearance

A reported effect can decline while drug remains measurable or while the measured concentration is still rising. That observation concerns the relationship between concentration and effect over time. It should not be described as proof that the body has already eliminated most of the drug.

Nor does reduced subjective intensity establish recovery of every function. Someone’s reported high is an outcome worth measuring, but it is not a substitute for attention, judgment, coordination or driving performance. The cited timing comparison did not validate a universal point at which people become fit to drive.

Why a single specimen cannot locate a person on every curve

A later plasma result supplies one observation at collection. To place it on a concentration–time trajectory requires assumptions about route, dose, repeated administration, absorption and elimination. To use it to locate a subjective or functional trajectory requires additional evidence linking those endpoints.

The review notes variable elimination half-lives and the importance of urinary pH. Its smoking discussion also considers possible contributions from swallowed material and delayed absorption. An investigator cannot select one historical average and assume that an unknown individual followed exactly the same path.

Plasma must also remain plasma. These reported values are not whole-blood measurements, and they should not be assigned directly to a whole-blood result without an adequately supported matrix comparison.

Questions that make a timing opinion clearer

Ask when administration reportedly began and ended; when each specimen and observation was obtained; whether more than one dose was possible; and whether “peak” means concentration, self-report or a measured task. Record the uncertainty instead of filling gaps with an average curve.

The defensible lesson is a temporal distinction: a subjective high can peak earlier than plasma concentration under the conditions summarized in this historical review. That finding challenges a one-clock interpretation while leaving individual impairment and event causation to a separate assessment.

Scientific source

Logan BK. Methamphetamine—Effects on Human Performance and Behavior. Forensic Science Review. 2002;14(1–2):133–151, sections IV.B and V.A. PubMed record, PMID 26256490. Historical review; study-level findings above are attributed to this secondary source.

A methamphetamine-positive homicide victim is not evidence that the perpetrator used methamphetamine. Nor does the victim’s concentration, by itself, establish why the violence occurred. This distinction is essential when historical death-investigation statistics are used to support claims about drug-related aggression.

What did the historical review describe?

Barry Logan’s 2002 review, Methamphetamine—Effects on Human Performance and Behavior, discusses selected death investigations and literature about violence. Its section on methamphetamine and violence reports blood methamphetamine concentrations in homicide victims ranging from less than 0.03 to 9.30 mg/L, with a median of 0.550 mg/L. These are measurements attributed to victims in a selected death-investigation series, not experimentally assigned exposures in people committing homicide.

This article examines that supplied review. The underlying case series and other studies summarized by Logan are secondary-source evidence here; they were not independently reanalyzed. Historical observations should not be presented as a current population rate or as a validated violence-prediction tool.

Three propositions that must remain separate

Exposure in the tested person: a properly confirmed result supports the presence of the analyte in that person’s specimen. Association with a manner of death: a series can describe how often a classification occurred among its included cases. Causation of an act: explaining why a specific person acted requires evidence about that actor, the event and competing explanations.

Moving from the first proposition to the third changes both the person being discussed and the conclusion being offered. Even if both victim and perpetrator had used a drug, one person’s concentration would not measure the other’s functional state or intent.

The denominator changes the meaning of the percentage

A proportion of methamphetamine-positive death investigations classified as homicide does not measure the proportion of all living methamphetamine users who commit homicide. It also does not describe all homicide perpetrators. Those populations have different selection rules and denominators.

Death-investigation samples condition on death and on entry into a particular jurisdiction’s testing process. They do not supply a comparison group of otherwise similar living people with and without exposure. A dramatic percentage cannot repair that missing comparison.

Association leaves several explanations open

Logan discusses social setting, victimization, psychiatric symptoms, weapons, impaired judgment and other potential contributors. The review expressly recognizes the limits of the evidence for a causal connection between use or concentration and violent behavior. A plausible mechanism is a hypothesis to evaluate, not proof that the mechanism explains a particular event.

The same care applies when a person is agitated, fearful or aggressive during an encounter. Those observations may be relevant, but they should be documented independently and examined with the timeline, medical history, sleep, co-exposures, injuries and circumstances. A positive result does not uniquely identify the cause of a behavior.

Does a high concentration settle the issue?

No concentration in this historical discussion was validated as a threshold for violent conduct, intent or responsibility. The fact that a homicide victim had a high blood result does not establish a fatal poisoning, a perpetrator’s intoxication, or drug-induced aggression. Cause of death and the circumstances of violence require their own evidence.

A scientifically bounded opinion identifies the tested person, specimen, collection context, analyte and units before addressing behavioral interpretation. It states whether the literature describes victims, perpetrators, arrested drivers or patients. That simple discipline prevents a statistical association from becoming an unsupported account of a person’s state of mind.

Scientific source

Logan BK. Methamphetamine—Effects on Human Performance and Behavior. Forensic Science Review. 2002;14(1–2):133–151, especially section VI.A. Verified PubMed bibliographic record, PMID 26256490. Historical narrative review; underlying studies are discussed through the supplied review.

A person’s age or sex cannot be used as a shortcut for estimating a blood amphetamine concentration from the 2007 study by Alan Wayne Jones. Among 300 apprehended drivers, increasing age had a weak statistical association with concentration, while the reported sex comparisons were not statistically significant. The study is useful for understanding population summaries, rather than predicting an individual result.

Who was included?

This historical observational study selected 300 Swedish suspected drug-impaired drivers whose testing identified amphetamine as the only psychoactive drug in blood. There were 246 men and 54 women. These were selected forensic cases, not a random sample of the public, a controlled dosing experiment, or a study of prescribed treatment.

The laboratory screened for specified drug classes and used more specific methods to confirm positive findings. Blood amphetamine was quantified by gas chromatography–mass spectrometry with a deuterated internal standard. The routine limit of quantitation was 0.03 mg/L. “Only drug identified” must be understood within the analytical scope; it is not proof that every possible substance was excluded.

A significant age association can still be weak

The reported age–concentration correlation was r = 0.18, with p < 0.05. The association was statistically significant, but its magnitude was small. Statistical significance addresses evidence against a specified null model; it does not mean age accurately predicts an individual’s concentration.

Squaring the reported correlation gives approximately 0.032, or 3.2%. As a descriptive calculation for a simple linear relationship, that illustrates the limited shared variation. It is not a validated prediction model, a causal estimate, or a measure of driving impairment.

Doses, routes and elapsed times were not assigned by the investigators. An observed association with age therefore cannot identify slower elimination as its cause. Differences in exposure histories, selection into the forensic sample and other unmeasured characteristics remain possible explanations.

Preserve the nonsignificant sex comparison

Recorded group	Number	Mean blood amphetamine	Median
Men	246	0.97 mg/L	0.8 mg/L
Women	54	1.11 mg/L	1.0 mg/L

The women’s mean was numerically higher, but the paper reported no statistically significant difference using either Student’s t-test or the Mann–Whitney test. Describing women as having a demonstrated higher concentration would overstate the result. Conversely, failure to find significance does not prove equivalence between the groups.

The unequal group sizes matter when assessing precision and generalizability. These summaries do not establish a biological explanation, a sex-specific dosing rule, or a correction factor for forensic interpretation.

A sample distribution is not a reference interval for safe driving

Across all 300 cases, the mean was 1.0 mg/L, the median 0.9 mg/L, and the reported 2.5th and 97.5th percentiles were 0.06 and 3.0 mg/L. Those percentiles describe this selected distribution. They are not therapeutic boundaries or a range in which drivers can be presumed safe.

The paper also examined clinical impairment in a separate, smaller retrospective sample of 70. That denominator should not be substituted for the 300-person demographic analysis or described as 300 clinical examinations. Age, concentration and an impairment classification are different variables.

What should an expert ask?

Identify which population generated the statistic, which analyte and specimen were measured, whether the comparison was significant, and whether prediction was actually validated. For a particular person, the measured result and its uncertainty take precedence over a demographic expectation. Dose, timing and functional conclusions each need additional support.

Scientific source

Jones AW. Age- and gender-related differences in blood amphetamine concentrations in apprehended drivers: lack of association with clinical evidence of impairment. Addiction. 2007;102:1085–1091. doi:10.1111/j.1360-0443.2007.01802.x. Original commentary on the supplied historical human observational study; no paper text, figures or source tables reproduced.

A positive methamphetamine screen and a confirmed methamphetamine concentration are different findings. Evaluating a laboratory packet requires identifying which analytical step supports each statement in the final report.

A published example of the sequence

In Lemos’s 2009 two-case driving report, blood underwent an enzyme-linked immunosorbent screening panel. Following a positive methamphetamine screen, a fresh aliquot was extracted and analyzed by gas chromatography–mass spectrometry using deuterated internal standards and quantitative calibrators.

The paper therefore described more than a presumptive screen. It reported a subsequent analytical process used to identify and quantify methamphetamine and amphetamine. That historical example does not mean every laboratory follows the same workflow.

Confirmation still requires method-specific scrutiny

Logan’s 2002 review discusses challenges in gas chromatographic identification, including structural similarities, chromatographic behavior and the need to assess retention information together with mass spectra. A mass spectrometer’s presence alone does not explain whether the laboratory met its identification criteria.

The appropriate record includes the validated method, calibrations, controls, chromatograms, identification criteria and the results relevant to the tested specimen. A case report can describe a method but cannot substitute for the actual case’s analytical records.

Negative panels have defined scope

Lemos reported negative findings on the other screens performed. That statement is limited to the included analytes and the capabilities of those methods. It does not establish that every possible substance was absent.

Similarly, the laboratory’s reporting limit is part of the result. An analyte not reported above a threshold should not automatically be described as absolutely absent, and screening results should not be treated as quantitative confirmations.

Keep the conclusion within the measurement

Record the specimen type, collection time, units, analytes and analytical uncertainty where available. Then separate chemical identification from interpretation. Confirmation can strengthen evidence that an analyte was present in the specimen; it does not independently establish the source, dose, time of administration or degree of impairment during earlier driving.

The central question is whether the disclosed data support the laboratory’s exact claim. Analytical accuracy and the subsequent behavioral inference each require their own justification.

Scientific sources

Lemos NP. Methamphetamine and driving. Science and Justice. 2009;49:247–249. Case report.

Logan BK. Methamphetamine—Effects on Human Performance and Behavior. Forensic Science Review. 2002;14(1–2):133–151. Historical review.

A stimulant can improve a measured task in a sleep-deprived person without demonstrating universal enhancement or safe driving. Historical amphetamine aviation research is useful precisely because it makes the baseline condition and the tested task central to interpretation.

Restoration and enhancement are different comparisons

In his 2002 review, Logan summarizes research on d-amphetamine during prolonged wakefulness. The review describes improvements in selected performance measures under sleep deprivation and distinguishes restoring degraded performance from exceeding the rested baseline.

Those comparisons answer different questions. A treated participant can perform better than a sleep-deprived placebo participant while still falling short of rested performance on another important measure. A claim about improvement must identify its comparator.

Simulator outcomes do not describe every real-world task

The review discusses helicopter simulator studies and related actual-flight work. It reports that effects in actual flight were less pronounced and became significant later in the sleep-deprivation period. That distinction argues against treating simulator scores and field performance as interchangeable.

It also describes historical military administration under flight-surgeon supervision. This is background about a past practice, not a recommendation for medication use or a statement of current military policy.

Why the regimen matters

The summarized evidence involved specified oral regimens and defined periods of wakefulness. It cannot be transferred unchanged to unknown doses, repeated high-intensity use, smoked or injected methamphetamine, or withdrawal after a binge. Amphetamine and methamphetamine also should not be silently substituted for one another when identifying what a study administered.

Logan’s discussion of prolonged use includes fatigue and sleepiness during the crash phase. Evidence that a controlled regimen improved selected fatigue-related outcomes does not establish that another dose reliably reverses that different clinical state.

Questions before applying the evidence

Identify the administered drug, baseline sleep condition, comparator, task, observation interval and measured outcome. Preserve differences between subjective alertness and objective performance. Where only a review has been examined, attribute the underlying study findings to that review rather than implying independent examination of the original trial.

The scientific lesson is specific: performance effects depend on the task and the person’s starting condition. Historical fatigue research cannot certify an individual’s fitness to drive or establish the cause of a particular incident.

Scientific source

Logan BK. Methamphetamine—Effects on Human Performance and Behavior. Forensic Science Review. 2002;14(1–2):133–151. This article analyzes the supplied historical review; studies discussed within that review are secondary-source evidence here.

A methamphetamine-to-amphetamine ratio can contribute to a pharmacokinetic interpretation, but a single ratio does not reliably determine an individual’s exact time of use. The parent drug and metabolite have different concentration-time profiles, and repeated doses can obscure their relationship.

Why the ratio changes

Logan’s 2002 review describes metabolism of methamphetamine to amphetamine. In the controlled oral studies summarized there, the methamphetamine peak preceded the peak of the amphetamine metabolite. Consequently, a relatively high parent-to-metabolite ratio could be compatible with more recent exposure under those experimental conditions.

The review explicitly cautions that multiple doses confound that interpretation. A later dose adds parent drug to a specimen that may already contain metabolite from earlier administrations. The resulting ratio need not resemble the curve after a single isolated dose.

The specimen must match the reference data

The review discusses plasma, serum, urine and saliva findings from different studies. A ratio measured in one compartment should not be assigned a timing rule developed in another without supporting validation. Urinary excretion and a circulating concentration are different measurements.

Reporting limits also matter. If amphetamine is below the method’s quantification limit, dividing the methamphetamine value by an assumed zero does not produce a meaningful quantitative clock. Units and the laboratory’s handling of low values must be explicit.

Elimination is variable

The historical review reports broad half-life ranges and notes the importance of urinary pH to methamphetamine disposition. Its controlled-dose summaries cannot supply an exact elimination rate for an unknown individual with uncertain dosing history.

Other potential sources of amphetamine or methamphetamine further complicate interpretation. A ratio should therefore be examined together with medication history, analyte confirmation and, where relevant, stereochemistry.

How to frame a forensic conclusion

Ask whether the proposed estimate comes from a validated model for the same specimen, population, route and dosing pattern. Distinguish a pattern compatible with recent use from a proven administration time. If several histories can generate the finding, disclose that ambiguity.

Finally, a time-of-use inference is not an impairment measurement. Even an improved estimate of exposure timing would still require a separate assessment of functional performance at the event.

Scientific source

Logan BK. Methamphetamine—Effects on Human Performance and Behavior. Forensic Science Review. 2002;14(1–2):133–151. This article analyzes the supplied historical review; studies discussed within that review are secondary-source evidence here.